Tirofiban is a medicine used to help prevent blood clots in people who have had a heart attack or are having a heart attack. It works by stopping platelets, which are tiny blood cells, from sticking together and forming clots. This helps keep the blood flowing smoothly in the heart and blood vessels.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Tirofiban, sold under the brand name Aggrastat and also available as a generic, is an intravenous antiplatelet medicine used in the hospital during a heart emergency. It is approved for people with non-ST elevation acute coronary syndrome (NSTE-ACS), a term covering unstable angina and the type of heart attack that does not show ST-segment elevation, a specific raised section of the heart tracing on an electrocardiogram (ECG) that signals a fully blocked artery. In both, a narrowed heart artery is partly blocked by a clot, and the goal is to stop that clot from growing. In the trials behind its approval, tirofiban lowered the combined rate of death, heart attack, ongoing chest pain from reduced blood flow, or the need for another urgent heart procedure. Care has changed since it was approved. Modern oral antiplatelet medicines and early catheter procedures (coronary angiography and stenting) now do much of the work, and current heart guidelines do not recommend giving drugs like tirofiban routinely. Cardiologists instead use it selectively, often during or around a catheter procedure, when they judge that the extra clot protection is worth the extra bleeding risk. Tirofiban has also been studied in acute ischemic stroke (a stroke caused by a blocked brain artery), mainly in trials in China. Pooled results suggest a modest improvement in how many people regain independence after three months, with more bleeding inside the brain seen on scans. This use is not approved in the United States and is not yet part of routine stroke care.
Platelets are small blood cells that clump together to form clots. When a fatty plaque inside a heart artery cracks, platelets gather at the site, and a protein called fibrinogen links them to one another by attaching to a receptor on their surface named glycoprotein IIb/IIIa (GP IIb/IIIa). Tirofiban occupies that receptor so fibrinogen cannot bridge the platelets, which blocks the final shared step of clumping no matter what triggered it. Because it acts at this last step, its effect is strong and fast. With the standard starting dose, more than 90% of platelet clumping is blocked within about 10 minutes. The effect is reversible and short-lived: once the infusion stops, platelet function returns close to normal within about 4 to 8 hours in most people. That quick on and off is useful in a hospital, where treatment can be adjusted or stopped if bleeding or a procedure requires it.
Tirofiban is given only in the hospital, through a vein. It starts with a quick loading dose over a few minutes, followed by a continuous drip, usually for up to 18 hours. The dose is calculated from body weight, and nurses run it through a pump. Because the kidneys clear most of the drug, the drip rate is cut in half for people whose kidney function is reduced, as estimated from a blood test. Tirofiban is almost always given together with other medicines that prevent clots, such as aspirin, an oral antiplatelet like clopidogrel, and an injectable anticoagulant such as heparin or bivalirudin. Patients do not manage any part of the dosing themselves.
Bleeding is the main side effect. Most of it happens where the catheter entered the artery, usually in the groin or wrist, and shows up as oozing, bruising or a firm, painful swelling at that spot. Minor bleeding from the gums, nose or needle sites can also occur. Other effects reported a little more often than with heparin alone include a slow heart rate, dizziness, sweating and leg or pelvic discomfort. Because the infusion is given in the hospital, the action for any warning sign is to tell the nurse right away. That includes new bleeding or swelling at the catheter site, blood in urine or stool, vomiting blood, a sudden severe headache, or trouble breathing, hives or swelling of the face soon after the drug is started, which can signal a rare severe allergic reaction. A small number of people develop a sharp drop in platelets, the cells that stop bleeding. It usually causes no symptoms on its own and is found on routine blood tests. Counts recover after the drug is stopped.
Tirofiban is not used in people who have active internal bleeding, a known bleeding disorder, or major surgery or a severe injury within the past month. It is also avoided in anyone who had a severe allergic reaction to it or a drop in platelets after receiving it before. Having had another drug of the same class (eptifibatide or abciximab) in the past may also raise the chance of low platelets, so the team will want to know about earlier heart procedures. The drugs most likely to add to bleeding are the ones usually given with it: anticoagulants (blood thinners such as heparin, warfarin or apixaban), other antiplatelet medicines (aspirin, clopidogrel, ticagrelor, prasugrel) and clot-dissolving drugs. These are combined on purpose, and the team balances the doses, but it matters to tell them about any blood thinner taken at home, recent surgery or injuries, past stomach or brain bleeding, and kidney disease. Only limited human data exist in pregnancy. Published case reports have not linked tirofiban to birth defects or miscarriage, and an untreated heart attack is itself dangerous to both mother and baby, so a pregnancy does not by itself rule it out. It is not known whether the drug passes into breast milk.
Tirofiban is part of a short, intensive phase of hospital care. People usually receive it in a cardiac unit or the catheterization lab, with heart monitoring and frequent checks of blood pressure, the catheter site and blood counts. Platelet levels are typically measured about 6 hours after the drip begins and then daily, and the drug is stopped, along with heparin, if counts fall too low. The infusion is temporary, usually for less than a day, and its effect fades within hours of stopping. Tirofiban itself is not continued after discharge. Longer-term protection comes from the oral medicines the care team prescribes before discharge, and any questions about bleeding risk after going home relate to those continuing medicines rather than to tirofiban.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tirofiban, what you've noticed, or ask the community a question.